Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23932
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEissmann, Moritz F-
dc.contributor.authorBuchert, Michael-
dc.contributor.authorErnst, Matthias-
dc.date2020-07-03-
dc.date.accessioned2020-08-03T06:35:51Z-
dc.date.available2020-08-03T06:35:51Z-
dc.date.issued2020-07-03-
dc.identifier.citationFrontiers in Immunology 2020; 11: 1389en
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/23932-
dc.description.abstractThe Interleukin (IL-)1 family IL33 is best known for eliciting type 2 immune responses by stimulating mast cells (MCs), regulatory T-cells (Tregs), innate lymphoid cells (ILCs) and other immune cells. MCs and IL33 provide critical control of immunological and epithelial homeostasis in the gastrointestinal (GI) tract. Meanwhile, the role of MCs in solid malignancies appears tissue-specific with both pro and anti-tumorigenic activities. Likewise, IL33 signaling significantly shapes immune responses in the tumor microenvironment, but these effects remain often dichotomous when assessed in experimental models of cancer. Thus, the balance between tumor suppressing and tumor promoting activities of IL33 are highly context dependent, and most likely dictated by the mixture of cell types responding to IL33. Adding to this complexity is the promiscuous nature by which MCs respond to cytokines other than IL33 and release chemotactic factors that recruit immune cells into the tumor microenvironment. In this review, we integrate the outcomes of recent studies on the role of MCs and IL33 in cancer with our own observations in the GI tract. We propose a working model where the most abundant IL33 responsive immune cell type is likely to dictate an overall tumor-supporting or tumor suppressing outcome in vivo. We discuss how these opposing responses affect the therapeutic potential of targeting MC and IL33, and highlight the caveats and challenges facing our ability to effectively harness MCs and IL33 biology for anti-cancer immunotherapy.en
dc.language.isoeng
dc.subjectST2en
dc.subjectcytokine signalingen
dc.subjectgastrointestinal (GI) malignanciesen
dc.subjectinnate immunityen
dc.subjectinterleukin 33 (IL33)en
dc.subjectmast cell (MC)en
dc.subjecttherapy targetsen
dc.subjecttumor microenvironment (TME)en
dc.titleIL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers?en
dc.typeJournal Articleen
dc.identifier.journaltitleFrontiers in Immunologyen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationLa Trobe University School of Cancer Medicine, Heidelberg, VIC, Australiaen
dc.identifier.doi10.3389/fimmu.2020.01389en
dc.type.contentTexten
dc.identifier.pubmedid32719677
dc.type.austinJournal Article
dc.type.austinReview
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Feb 7, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.